2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Nitin Jain, MD, assistant professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses the treatment of patients with chronic lymphocytic leukemia who have developed Richter’s transformation.
Nitin Jain, MD, assistant professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses the treatment of patients with chronic lymphocytic leukemia (CLL) who have developed Richter’s transformation.
Richter’s transformation remains an unmet medical need, says Jain. Most of the targeted therapies for CLL have not been successful in patients with Richter’s transformation.
Checkpoint blockade is a valid concept, Jain says, as well as chimeric antigen receptor (CAR) T-cell therapies—studies of which will come out in the next few years.